PCa Commentary #172 – METASTASES DIRECTED THERAPY (MDT): Can Concomitant Hormone Suppression Be Avoided?

by Dr. Ed Weber | Dec 28, 2022 | PCa Commentary

Metastases Directed Therapy refers to targeted radiation, i.e., such as CyberKnife, directed at a few metastatic lesions, (osseous or nodal), usually 3 – 5, for the purpose of controlling all imageable disease, delaying cancer progression and, if not accompanied...

PCa Commentary #171 – Nonmetastatic Castration-Resistant Prostate Cancer: The “Ides” of Androgen Receptor Inhibition – Enzalutamide, Apalutamide and Darolutamide.

by Dr. Ed Weber | Nov 8, 2022 | PCa Commentary

Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a transient, heterogeneous state that progresses to metastatic disease. nmCRPC is defined as a rising PSA after primary therapy in association with a castrate level of testosterone (<50 ng/mL) while...

PCa Commentary #170 – ACTIVE SURVEILLANCE (AS) for Men with Favorable-Intermediate Risk (F-IR) Prostate Cancer: Patient Selection and the Role of MRI Monitoring.

by Dr. Ed Weber | Oct 25, 2022 | PCa Commentary

The key to optimal outcomes in active surveillance is careful patient selection and monitoring of participants during AS. MRI guided biopsy at initial diagnosis: Lee et al., Korean J Radiol. 2021 Jul, argue that in men in whom there is a clinical suspicion of prostate...

PCa Commentary #169 – ANDROGEN DEPRIVATION THERAPY (ADT) and Radiotherapy: Basic Mechanisms and New Developments.

by Dr. Ed Weber | Sep 21, 2022 | PCa Commentary

Any man diagnosed with prostate cancer is likely aware that lowering testosterone (T) levels achieves control of the cancer at various stages of the disease. Question: What is the underlying biology and function of that therapeutic maneuver (androgen deprivation...

PCa Commentary #168 – De Novo Metastatic Castration-Sensitive Prostate Cancer: (mHSPC) — Many Options for Treatment

by Dr. Ed Weber | Aug 24, 2022 | PCa Commentary

The incidence of metastatic prostate cancer at diagnosis, i.e., metastatic hormone-sensitive prostate cancer has increased, partly due to the fallout from the 2012 Task Force recommendation against screening, particularly increasing in men older than 75 years. This...

PCa Commentary #167 – PROVENGE – AN UPDATE: What Has Been Learned Since FDA  Approval in 2010?

by Dr. Ed Weber | Jul 20, 2022 | PCa Commentary

Provenge (Dendreon, Inc, ‘Sipuleucel-T’) is an autologous (i.e., based on a patient’s own cells) vaccine targeted to the highly expressed prostatic acid phosphatase (PAP) antigen on malignant prostate cells. It was FDA approved based on the IMPACT trial reporting a...